Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Insmed (INSM) PT Raised to $43 at Morgan Stanley
May 9, 2024 12:11 PM EDTMorgan Stanley analyst Jeffrey Hung raised the price target on Insmed (NASDAQ: INSM) to $43.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "Insmed reported 1Q Arikayce sales of $75.5M (consensus: $78M) and reiterated guidance 2024 Arikayce revenue guidance of $340M-360M. The company... More
